Trans advanced surface laser ablation outcomes using SmartPulseTechnology for hyperopia

Abstract

To evaluate the safety and efficacy of Transepithelial photorefractive keratectomy (TransPRK) for hyperopia using SmartPulseTechnology (SPT). The study included 108 eyes (56 patients) with hyperopia (0.50 to 7.25 diopters [D]), with or without astigmatism (0.00 to-3.00 D), who underwent single-step transepithelial PRK with Amaris 500 -Hz excimer laser (SCHWIND eye technology) solutions, Kleinostheim, Germany). Two groups were formed as hypermetropia below three and above 3. A 6-month follow-up was performed. Preoperative and postoperative visual acuity, preoperative and postoperative manifest refraction, and postoperative corneal hase were compared. Postoperative uncorrected visual acuity (UCVA) was 0.006 ± 0.018 logmar in group 1 and 0.022±0.034 logmar in group 2. When the groups were compared, there was a statistically significant difference between preoperative and postoperative UCVA. (p<0.01) The mean preoperative spherical equivalent value was 2.47±1.01 and 5.75±1.32 diopters, respectively. The mean postoperative spherical equivalent value was 0.16±0.24 and 0.32±0.27 diopters, respectively. No corneal hase was found in both group in the 6th postoperative month. There was no difference between the groups in the postoperative spherical equivalent. (p=0.374) TransPRK using SPT is promising in achieving the target refractive value in low and moderate hyperopia. This method allows patients to everyday-quickly return to normal life due to the rapid recovery process and low corneal damage rate.